RxDoctor Payments DataLook up a doctor →

John Dvorak, MD

Colon & Rectal Surgery · Lexington, KYNPI 1902807985

Payments from drug & device makers

$13,165in general payments, 2019–2025

Across 544 payments — averaging $24.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • AbbVie$2K
  • Johnson & Johnson$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$783
  • Davol Inc.$538
  • plus $4K from 39 others

What the payments were for

  • Travel & lodging$8597%
  • Food & beverage$11,27886%
  • Education$1,0298%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,165 in reported general payments places this provider in the 70th percentile of 28 colon & rectal surgery providers in Kentucky.

See all colon & rectal surgery providers in Kentucky

Medicare billing

Part B allowed, 2024
$132,770
Medicare patients
242
Services billed
2,509

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab36$998,585
TrulancePlecanatide14$7,679
Mesalamine19$6,745
Colestipol Hcl45$5,932
Budesonide DrBudesonide50$5,659
MovantikNaloxegol Oxalate12$5,601
Mesalamine ErMesalamine19$1,690
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav39$484
Neomycin Sulfate45$278
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen64$219
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl16$191
Metronidazole53$160
Nortriptyline Hcl13$125

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,509$998,58536 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$1,889$7,67914 claims
Redhill Biopharma Inc.Movantik$51$5,60112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 28 colon & rectal surgery providers in Kentucky.

Other colon & rectal surgery in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →